GlassScriptPhysician profile
Michelle A Armstrong
NPI 1316287790
$2,800.42
in general payments reported to CMS, 2019-2025
31 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $531 · 2023: $456 · 2024: $656 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.93 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $285.62 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $230.39 | 2024-2025 | Imbruvica, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $217.56 | 2022-2025 | |
| Sobi, INC | $202.57 | 2022-2025 | |
| Pfizer INC. | $199.69 | 2022-2025 | |
| Abbvie INC. | $197.18 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $175.35 | 2022-2025 | Libtayo |
| Celgene Corporation | $152.94 | 2022-2024 | Reblozyl |
| Glaxosmithkline, LLC. | $151.55 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $124.62 | 2022-2025 | Enhertu |
| Seagen INC. | $98.92 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Jazz Pharmaceuticals INC. | $92.09 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $84.45 | 2023-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $73.41 | 2022 | |
| Beone Medicines USA, INC. | $63.11 | 2025 | Brukinsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.97 | 2022-2025 | Opdivo |
| Eisai INC. | $48.42 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.86 | 2024-2025 | |
| Stemline Therapeutics INC. | $41.02 | 2024-2025 | Orserdu |
| Adc Therapeutics America, INC. | $36.89 | 2023-2025 | |
| Gilead Sciences, INC. | $31.54 | 2024-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $31.52 | 2022-2024 | Xpovio |
| Blueprint Medicines Corporation | $20.73 | 2022 | |
| Acrotech Biopharma INC. | $20.56 | 2025 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $19.63 | 2023 | Tavalisse, Rezlidhia |
| Pharmaessentia USA Corporation | $18.82 | 2025 | Besremi |
| Coherus Oncology, INC. | $16.75 | 2022 | |
| Dendreon Pharmaceuticals LLC | $14.93 | 2025 | Provenge |
| Geron Corporation | $14.55 | 2025 | Rytelo |
| Incyte Corporation | $14.43 | 2025 | Jakafi |
| Aroa Biosurgery Incorporated | $14.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.